The effect of cyclosporine cream on rosacea

Phase 2

Recruiting

• Conditions: Erythematotelangiectatic or papulopustular rosacea.; Rosacea

• Registration Number: IRCT20190901044666N2
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients aged 15 to 50 years
Patients with a confirmed diagnosis of erythematotelangiectatic or papulopustular rosacea or a combination of both
The patient has not received treatment for his or her disease in the past two months
Absence of a serious underlying disease
Patient's cooperation in the implementation of therapeutic measures and participation in all therapeutic sessions

Exclusion Criteria

The occurrence of a sensitivity or adverse reaction to any of the therapeutic agents that prevents continuation of treatment
The occurrence of bacterial or viral skin disease during treatment or the follow-up period

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluating the severity of the disease. Timepoint: One, two, three and five months after starting treatment. Method of measurement: By the total severity score of rosacea.

Secondary Outcome Measures

Name	Time	Method
Doctor and patient satisfaction. Timepoint: One, two, three and five months after starting treatment. Method of measurement: Caregiver treatment satisfaction (CTS) questionnaire scale.;Safety. Timepoint: One, two, three and five months after starting treatment. Method of measurement: Examining the side effects of the treatment with a questionnaire.;Tolerability. Timepoint: One, two, three and five months after starting treatment. Method of measurement: with the Investigator Assessment of Tolerability scale.